Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorenzo Antonuzzo

Showing results (1-10 of 237) with videos related to

Pageof 24
Sort By:
Critical Reviews in Oncology/Hematology|October 16, 2024
Corrigendum to "The emerging HER2 landscape in Colorectal Cancer: The key to unveil the future treatment algorithm?" [Crit. Rev. Oncol./Hematol. 204 (2024) 104515]Lorenzo Antonuzzo
European Urology|September 28, 2025
Re: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, et al. Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.07.002Giandomenico Roviello, Lorenzo Antonuzzo
European Urology|May 1, 2026
Re: Perioperative enfortumab vedotin and pembrolizumab in bladder cancerGiandomenico Roviello, Lorenzo Antonuzzo
European Urology|January 14, 2026
Re: Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial CancerGiandomenico Roviello, Silvia Mancini, Lorenzo Antonuzzo
Cancer Research|February 21, 2024
Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy EfficacyGiulia Petroni, Serena Pillozzi, Lorenzo Antonuzzo
Cancer|October 9, 2025
From treatment escalation to ultra de-intensification: When androgen-deprivation therapy alone remains a rational choice in metastatic hormone-sensitive prostate cancerGiandomenico Roviello, Martina Catalano, Lorenzo Antonuzzo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2013
Are circulating tumor cells a new, valid prognostic marker in neuroendocrine tumors?Lorenzo Antonuzzo, Giulia Meoni, Francesco Di Costanzo
European Urology|January 13, 2026
Re: ctDNA-guided Adjuvant Atezolizumab in Muscle-invasive Bladder CancerGiandomenico Roviello, Ismaela Anna Vascotto, Lorenzo Antonuzzo
The Journal of Urology|July 7, 2023
Editorial CommentRiccardo Campi, Alessio Pecoraro, Lorenzo Antonuzzo, et al.
Heliyon|May 2, 2024
Unconventional strategy could be the future: From target to KRAS broad range treatmentSara Fancelli, Giulia Petroni, Serena Pillozzi, et al.
Pageof 24

Showing results (1-10 of 237) with videos related to

Sort By:
Pageof 24
Critical Reviews in Oncology/Hematology|October 16, 2024
Corrigendum to "The emerging HER2 landscape in Colorectal Cancer: The key to unveil the future treatment algorithm?" [Crit. Rev. Oncol./Hematol. 204 (2024) 104515]Lorenzo Antonuzzo
European Urology|September 28, 2025
Re: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, et al. Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.07.002Giandomenico Roviello, Lorenzo Antonuzzo
European Urology|May 1, 2026
Re: Perioperative enfortumab vedotin and pembrolizumab in bladder cancerGiandomenico Roviello, Lorenzo Antonuzzo
European Urology|January 14, 2026
Re: Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial CancerGiandomenico Roviello, Silvia Mancini, Lorenzo Antonuzzo
Cancer Research|February 21, 2024
Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy EfficacyGiulia Petroni, Serena Pillozzi, Lorenzo Antonuzzo
Cancer|October 9, 2025
From treatment escalation to ultra de-intensification: When androgen-deprivation therapy alone remains a rational choice in metastatic hormone-sensitive prostate cancerGiandomenico Roviello, Martina Catalano, Lorenzo Antonuzzo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2013
Are circulating tumor cells a new, valid prognostic marker in neuroendocrine tumors?Lorenzo Antonuzzo, Giulia Meoni, Francesco Di Costanzo
European Urology|January 13, 2026
Re: ctDNA-guided Adjuvant Atezolizumab in Muscle-invasive Bladder CancerGiandomenico Roviello, Ismaela Anna Vascotto, Lorenzo Antonuzzo
The Journal of Urology|July 7, 2023
Editorial CommentRiccardo Campi, Alessio Pecoraro, Lorenzo Antonuzzo, et al.
Heliyon|May 2, 2024
Unconventional strategy could be the future: From target to KRAS broad range treatmentSara Fancelli, Giulia Petroni, Serena Pillozzi, et al.
Pageof 24